Nick joins CHARM with over two decades’ experience in preclinical development, translational research, and drug discovery. Previously, he was Chief Technology Officer at Mission Therapeutics where he contributed to the development of the company’s proprietary drug discovery platform. Prior to this, Nick worked as the Head of New Modalities, Drug Safety and Metabolism at AstraZeneca, after 12 years at Pfizer working within Discovery and Preclinical Development functions in both the UK and the US.
Nick holds a BSc in Pharmacology from the University of Leeds and a PhD from the University of Bath.
